Davita Inc (DVA) Shares Bought by Andra AP fonden
Andra AP fonden grew its stake in Davita Inc (NYSE:DVA) by 7.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,900 shares of the company’s stock after buying an additional 8,700 shares during the quarter. Andra AP fonden owned 0.08% of Davita worth $9,090,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in DVA. Vigilant Capital Management LLC lifted its position in shares of Davita by 250.0% in the second quarter. Vigilant Capital Management LLC now owns 2,100 shares of the company’s stock worth $146,000 after purchasing an additional 1,500 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Davita in the second quarter worth $206,000. Green Square Capital LLC bought a new stake in shares of Davita in the second quarter worth $208,000. IFG Advisory LLC bought a new stake in shares of Davita in the second quarter worth $213,000. Finally, Jane Street Group LLC bought a new stake in shares of Davita in the first quarter worth $243,000. Institutional investors own 87.75% of the company’s stock.
Shares of DVA stock opened at $68.36 on Thursday. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.88 and a current ratio of 1.90. The firm has a market capitalization of $11.96 billion, a PE ratio of 20.59, a price-to-earnings-growth ratio of 0.92 and a beta of 1.08. Davita Inc has a 12 month low of $52.51 and a 12 month high of $80.71.
A number of brokerages have recently commented on DVA. ValuEngine raised shares of Davita from a “hold” rating to a “buy” rating in a research report on Tuesday, October 9th. Zacks Investment Research raised shares of Davita from a “hold” rating to a “buy” rating and set a $78.00 price objective on the stock in a research report on Monday, July 9th. Finally, JPMorgan Chase & Co. raised shares of Davita from an “underweight” rating to a “neutral” rating in a research report on Thursday, September 13th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $82.50.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More: Dividend Aristocrat Index
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.